Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This study is looking at the effects of Ipilimumab when it is given alone or in combination
with Nivolumab to patients with relapsed or refractory classic Hodgkin's lymphoma (cHL).
The names of the study drugs involved in this study are:
- Ipilimumab
- Nivolumab